trimetrexate has been researched along with Diffuse Large B-Cell Lymphoma in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robson, C | 1 |
| Meek, MA | 1 |
| Grunwaldt, JD | 1 |
| Lambert, PA | 1 |
| Queener, SF | 1 |
| Schmidt, D | 1 |
| Griffin, RJ | 1 |
1 other study available for trimetrexate and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Survival; Folic Acid Antagonists; Indicators and Reagents; Kine | 1997 |